Reslizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Reslizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from rat)
Target IL-5
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
Chemical data
Formula ?
 YesY (what is this?)  (verify)

Reslizumab is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways, skin and gastrointestinal tract.[1] As of September 2009, the drug is undergoing Phase II/III clinical trials.[2]

References[edit]

  1. ^ Walsh, GM (2009). "Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions". Current opinion in molecular therapeutics 11 (3): 329–36. PMID 19479666. 
  2. ^ ClinicalTrials.gov